-
LadRx Corporation OTC Markets OTCPK:LADX LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.
Location: 11726 San Vicente Boulevard, Los Angeles, CA, 90049, United States | Website: https://www.ladrxcorp.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
580.2K
Cash
206.9K
Avg Qtr Burn
-464.3K
Short % of Float
0.51%
Insider Ownership
1.32%
Institutional Own.
0.00%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Arimoclomol Details Niemann Pick Disease Type C | NDA Resubmission | |
Aldoxorubicin Details Pancreatic cancer | Phase 2 Update | |
Aldoxorubicin Details Soft tissue sarcoma, Cancer | Phase 2 Update | |
Arimoclomol Details Inclusion Body Myositis | Failed Discontinued | |
Arimoclomol Details Amyotrophic lateral sclerosis | Failed Discontinued |